Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation

Página do item simplificado
dc.creatorGustavo Fernandes
dc.creatorDaniel Girardi
dc.creatorJoão Paulo Bernardes
dc.creatorFelipe Paiva Fonseca
dc.creatorEduardo Fregnani
dc.date.accessioned2023-10-16T19:32:11Z
dc.date.accessioned2025-09-09T00:11:29Z
dc.date.available2023-10-16T19:32:11Z
dc.date.issued2018-09-12
dc.identifier.doihttps://doi.org/10.1186%2Fs12885-018-4802-y
dc.identifier.issn14712407
dc.identifier.urihttps://hdl.handle.net/1843/59466
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofBMC Cancer
dc.rightsAcesso Aberto
dc.subjectAmeloblastoma
dc.subjectNeoplasms
dc.subjectMandible
dc.subject.otheropen acess Clinical benefit and radiological response with braf inhibitor in a patient with recurrent ameloblastoma harboring v600e mutation busca dia 09 09 2023 assunto ameloblastoma fao clinica
dc.titleClinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation
dc.typeArtigo de periódico
local.citation.issue1
local.citation.spage887
local.citation.volume18
local.description.resumoBackground: Ameloblastoma is a slow-growing neoplasm of the jaw, for which the standard treatment is surgical removal of the lesion with high recurrence rates and elevated morbidity. Systemic therapy is not established in the literature. Case presentation: We present a case of a 29-year-old woman diagnosed with an ameloblastoma of the left mandible who had been subjected to several surgical procedures over twenty years due to multiple local recurrences. Molecular testing revealed a BRAF V600E mutation, and vemurafenib was started. She experienced complete resolution of symptoms related to the disease, and image scans evidenced continuous shrinkage of the neoplastic lesion after eleven months of therapy. Conclusion: This is the first report showing clinical benefit and radiological response with vemrafenib for recurrent ameloblastoma. Targeted therapy addressing BRAF V600E mutation has the potential to change clinical practice of this rare disease.
local.publisher.countryBrasil
local.publisher.departmentFAO - DEPARTAMENTO DE CLÍNICA
local.publisher.initialsUFMG
local.url.externahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134697/

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.pdf
Tamanho:
967.33 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG